Skip to comments.Junking ObamaCare Might Help Bristol-Myers Squibb
Posted on 04/17/2012 3:17:13 PM PDT by Oldeconomybuyer
If ObamaCare is sent to history's junk pile, who wins in the medical sector?
For now, legislation already has saddled Bristol-Myers Squibb (BMY) with a number of burdens. For example, the minimum rebate on Medicaid drug sales was increased from about 15% to about 23%.
Bristol-Myers Squibb estimates all the ObamaCare fees and changes implemented so far cost the company 10 cents a share in 2010 and 24 cents a share in 2011.
Earnings per share increased 17% in 2010, but would've grown 22% without ObamaCare. Last year, earnings rose 6%. Without the new law, EPS would've grown 12%.
(Excerpt) Read more at news.investors.com ...
This is Great. ZeroCare is a Product of Drug Companies. And now it’s coming home to even Those short sighted scum.
I got your Bristol Meyers Squibb for you. Right Here: BMY’s own noxious, disgusting, Abilify.
And BTW: the stuff is Literally a Brain Eater
Hinckley, you’ve told us you’re a Psychiatrist on other posts here. Do you receive any honoraria or speakers fees from these cretins? If you’re a Psychiatrist how can you Not know what BMS and their Abilify are?
Do you prescribe this stuff to people? And if you do do you tell them what it Really Is?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.